Program
Azacitidine
Also written as “azacitidine”, “Azacitidine (AZA)” and “Eganelisib in combination with azacitidine”.
Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Lymphoma, T-Cell, led by 9 companies.
Drug pageAzacitidine: every studyMany companies study it; this page follows only the 27 they lead. All 441 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 161 open or running | phase 4since Sep 13, 2010 | Oct 31, 2003 | none ahead |
| Takedaits history only | 30 open or running | phase 3since Aug 30, 2017 | May 28, 2009 | none ahead |
| Hikma Pharmaceuticalsits history only | 21 open or running | phase 1since Mar 11, 2024 | Mar 11, 2024 | none ahead |
| Bioniche Pharma USAits history only | 10 open or running | phase 1since Jun 25, 2010 | Jun 25, 2010 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 2since Feb 7, 2020 | Feb 7, 2020 | none ahead |
| Merckits history only | 10 open or running | phase 2since Nov 24, 2014 | Nov 24, 2014 | none ahead |
| Nanexa ABits history only | 10 open or running | phase 1since May 11, 2021 | May 11, 2021 | none ahead |
| Nob Hill Therapeuticsits history only | 11 open or running | phase 2since Sep 10, 2026 | Sep 10, 2026 | Jul 13, 2029phase 2 · NCT07864584 |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Oct 4, 2006 | Oct 4, 2006 | none ahead |
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical, Hoffmann-La Roche, Roche-Genentech, Takeda Development Center Americas and argenx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Oct 31, 2003.
- Sep 11, 2007Phase 1 study in Myelodysplastic SyndromesNCT00528983 · 133 enrolled · United States
- Apr 1, 2008Phase 1 study in Multiple MyelomaNCT00652626 · 31 enrolled · United States
- Apr 23, 2008Phase 2 study in Leukemia, Myeloid, AcuteNCT00666497 · 6 enrolled · United States, Canada, United Kingdom
- Sep 25, 2008Phase 1 study in Leukemia, Myeloid, AcuteNCT00761722 · 31 enrolled · United States
- Feb 16, 2010Phase 3 study in Leukemia, Myeloid, AcuteNCT01074047 · 488 enrolled · United States, Australia, Austria and more
- Aug 20, 2010Phase 3 study in Myelodysplastic SyndromesNCT01186939 · 40 enrolled · Australia, Bulgaria, France and more
- Sep 13, 2010Phase 4 study in Myelodysplastic SyndromesNCT01201811 · 44 enrolled · Taiwan
- May 19, 2011Phase 2 study in Leukemia, Myeloid, AcuteNCT01358734 · 88 enrolled · United States, Canada
- May 14, 2012Phase 2 study in Myelodysplastic SyndromesNCT01599325 · 72 enrolled · China
- Apr 14, 2015Phase 2 study in Myelodysplastic SyndromesNCT02447666 · 28 enrolled · Austria, Belgium, Czechia and more
- May 19, 2015Phase 2 study in Leukemia, Myeloid, AcuteNCT02450877 · 7 enrolled · Denmark, Germany, Netherlands
- Feb 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteNCT02677922 · 130 enrolled · United States, Australia, Belgium and more
- Oct 9, 2018Phase 3 study in Lymphoma, T-CellNCT03703375 · 93 enrolled · Japan
- Feb 2, 2021Phase 1 study in Leukemia, MyeloidNCT04748848 · 1 enrolled · United States, Belgium, France and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04748848Leukemia, Myeloid · United States, Belgium, France and more | 1 | Terminated | Mar 9, 2022 | 1 |
| NCT03703375Lymphoma, T-Cell · Japan | 3 | Completed | Feb 10, 2021 | 93 |
| NCT02677922Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 2 | Active, not recruiting | Aug 2, 2018 | 130 |
| NCT02450877Leukemia, Myeloid, Acute · Denmark, Germany, Netherlands | 2 | Completed | Oct 10, 2018 | 7 |
| NCT02447666Myelodysplastic Syndromes · Austria, Belgium, Czechia and more | 2 | Completed | Feb 28, 2018 | 28 |
| NCT01599325Myelodysplastic Syndromes · China | 2 | Completed | Jan 29, 2015 | 72 |
| NCT01358734Leukemia, Myeloid, Acute · United States, Canada | 2 | Completed | May 19, 2015 | 88 |
| NCT01201811Myelodysplastic Syndromes · Taiwan | 4 | Completed | May 1, 2013 | 44 |
| NCT01186939Myelodysplastic Syndromes · Australia, Bulgaria, France and more | 3 | Completed | Sep 1, 2009 | 40 |
| NCT01074047Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Completed | Jan 22, 2014 | 488 |
| NCT00761722Leukemia, Myeloid, Acute · United States | 1 | Completed | Apr 6, 2016 | 31 |
| NCT00666497Leukemia, Myeloid, Acute · United States, Canada, United Kingdom | 2 | Terminated | Apr 2009 | 6 |
| NCT00652626Multiple Myeloma · United States | 1 | Completed | Jul 1, 2012 | 31 |
| NCT00528983Myelodysplastic Syndromes · United States | 1 | Completed | Jul 31, 2013 | 133 |
| NCT00102687Myelodysplastic Syndromes · United States | 2 | Completed | Aug 1, 2008 | 151 |
| NCT00071799Myelodysplastic Syndromes · United States, Australia, Bulgaria and more | 3 | Completed | Jul 1, 2007 | 358 |
How it is read
Names in the registry
- “Azacitidine”, 36 entries
- “azacitidine”, 8 entries
- “Azacitidine (AZA)”, 2 entries
- “Eganelisib in combination with azacitidine”, 1 entry
- “NHT102”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 30 studies
- Myelodysplastic Syndromes, 18 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hematologic Neoplasms, 1 study
- Lymphoma, T-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.